GE share Acq. of Amersham
General Electric Company
10 October 2003
GE Amersham
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA OR JAPAN.
NOT FOR RELEASE UNTIL 7:00 AM GMT ON 10 OCTOBER 2003
Recommended share exchange acquisition
by
General Electric Company and GE Investments, Inc.
of
Amersham plc
Summary of the Acquisition
• GE and Amersham announce their agreement on the terms of a recommended
share exchange acquisition by GE of Amersham.
• The making of the Acquisition is subject to the satisfaction or waiver
of certain regulatory pre-conditions and is expected to be effected by means of
a scheme of arrangement under section 425 of the Companies Act.
• Applying the Exchange Ratio on the basis of the Sterling GE Price at
Announcement of £18.32, Amersham Shareholders would be entitled to 0.4367 New GE
Shares for every Amersham Share held. On this basis, the terms of the
Acquisition value each Amersham Share at 800 pence and the diluted share capital
of Amersham at approximately £5.7 billion ($9.5 billion).
• These terms represent a premium of approximately 45 per cent. over the
price of an Amersham Share of 552 pence as at the close of business on 7 October
2003, the last trading day prior to the announcement by Amersham that it had
received an approach.
• Upon completion of the Acquisition, Sir William Castell will become a
Vice Chairman and member of the Board of Directors of General Electric and, as
CEO of GE Healthcare Technologies, will have financial and leadership
responsibility for GE Healthcare Technologies, the combined Amersham and GE
Medical businesses. Sir William Castell will also lead the integration process
to deliver the expected operating synergies. Joseph Hogan, Senior Vice
President of General Electric, will continue to lead the GE Medical business.
The GE Healthcare Technologies business will be based with Sir William Castell
in the UK.
• The Acquisition will be made in exchange for New GE Shares based on an
Exchange Ratio which will be finally determined at Completion. The Exchange
Ratio is subject to certain adjustments depending on movements in the Sterling
GE Price up to the Completion Date.
- If the Sterling GE Price at Completion is below the Sterling GE Price at
Announcement, the Exchange Ratio will increase to provide that Amersham
Shareholders continue to receive New GE Shares with a value in sterling of 800
pence, save that in no circumstances shall GE deliver pursuant to the
Acquisition more than the Maximum Exchange Ratio of 0.5571 New GE Shares per
Amersham Share.
- The Maximum Exchange Ratio would be reached if the Sterling GE Price at
Completion declined to £14.36, which is 21.6 per cent. lower than the Sterling
GE Price at Announcement.
- If the Sterling GE Price at Completion is above the Sterling GE Price at
Posting (the period between Posting and Completion is expected to be
approximately 6 weeks), the Exchange Ratio (as determined at Posting) will
remain fixed until the value in sterling of the New GE Shares to be received
equals 808 pence per Amersham Share and will then be reduced proportionately to
maintain a maximum value in sterling of 808 pence per Amersham Share at
Completion. The Exchange Ratio at Posting will be set out in the Acquisition
Document.
- Once the value per Amersham Share determined by the Exchange Ratio has
reached 808 pence there will be no limit to the proportionate reduction in the
number of New GE Shares which would be received under the Acquisition as the
Sterling GE Price increases.
• The acquisition of Amersham, a global leader in diagnostic imaging
agents and in life sciences, significantly advances General Electric's strategy
of addressing high-growth, high-technology segments of the global healthcare
industry. Amersham's imaging agents and biosciences businesses will add new,
high-technology platforms to GE Medical's diagnostic imaging, healthcare
services and information technology businesses, positioning GE Medical to
participate in exciting new developments in molecular imaging and personalised
medicine.
• The combination of Amersham and GE Medical is expected by General
Electric to be non-dilutive to 2004 earnings per share (before in-process
research and development charges) and $0.01 accretive in 2005. General Electric
expects to generate revenue synergies by the end of the third full year in the
order of $350 million to $400 million per annum, which are expected to translate
into operating profit synergy benefits of $100 million to $200 million per
annum. General Electric expects the revenue synergies to be achieved through a
variety of means, including access to new channels for each company's products
and services, channel efficiencies, accelerated global expansion and new product
introductions. Similarly, General Electric expects to achieve cost synergies
for the combined business in the range of $300 million to $400 million per annum
by the end of the third full year, an amount that represents approximately 3 per
cent. of the combined businesses' total cost base. General Electric expects
these cost synergies to be achieved through a variety of means including
improved sourcing, reduced general and administration and global infrastructure
costs and operating efficiencies across the combined businesses. General
Electric expects approximately half of these revenue and cost synergies to be
achieved by the end of the first full year following the Acquisition.*
* The foregoing statements as to financial accretion are not intended to mean
that General Electric earnings or earnings per share for any period will
necessarily exceed those of any prior year.
• The Amersham Board, which has been so advised by JPMorgan and Morgan
Stanley, considers the terms of the Acquisition to be fair and reasonable. In
providing advice to the Amersham Board, JPMorgan and Morgan Stanley have taken
into account the commercial assessment of the Amersham Board. Accordingly, the
Amersham Board intends unanimously to recommend that Amersham Shareholders vote
in favour of the Scheme (or, if applicable, accept the Offer) as the directors
of Amersham have undertaken to do in respect of their own respective beneficial
holdings of Amersham Shares (representing, in aggregate, approximately 0.05 per
cent. of the Amersham Shares currently in issue).
Commenting on the acquisition, Jeffrey R. Immelt, Chairman of the Board and
Chief Executive of General Electric, said:
'GE and Amersham will be an exciting combination of talents, businesses and
technologies. Amersham's diagnostic pharmaceutical and life sciences business
will add new, high growth platforms to GE Medical's diagnostic imaging, services
and healthcare information technology businesses. The combination of this
technological and market knowledge will allow GE to accelerate the development
of molecular imaging and personalised medicine where it will be possible to
predict and treat disease with therapies tailored to the individual.
We're delighted to bring Sir William Castell and his team to GE to help make
this vision a reality.'
Donald Brydon, Chairman of Amersham, said:
'The combination of these businesses represents good value for our shareholders
and is good news for our customers and employees.'
Sir William Castell, Chief Executive of Amersham, said:
'Combined with the complementary capabilities of General Electric this
transaction enables us to accelerate the realisation of our vision of
personalised medicine. We will have the competencies, the marketing reach and
the financial resources to bring disease prediction, diagnosis and personalised
treatment into the mainstream of medical practice. Our customers should now
raise their expectations as to what is deliverable from this new chapter in
medicine.'
The Acquisition and the posting of the Acquisition Document are subject to
certain Pre-Conditions relating to the obtaining of certain regulatory
clearances in the European Union and the United States. GE and Amersham intend
to proceed with the Acquisition through despatching the formal Acquisition
Document as soon as practicable after these Pre-Conditions are satisfied or
waived.
The Acquisition will be subject to the applicable rules and regulations of the
UK Listing Authority, the London Stock Exchange and the City Code. In addition,
the Acquisition will be subject to the applicable requirements of the United
States federal and state securities laws and the applicable rules and
regulations of the NYSE (except to the extent exempt from such requirements) as
well as applicable Norwegian rules and regulations.
This summary should be read in conjunction with the full text of this
announcement.
GE has been advised by Goldman Sachs. Amersham has been advised jointly by
JPMorgan and Morgan Stanley.
There will be a joint analysts and investors presentation in London at 9:00 AM
GMT (4:00 AM EDT) today at Goldman Sachs International, Rivercourt Building, 120
Fleet Street, London EC4A 2BB with a web-casting facility on Amersham's web site
(www.amersham.com). There will also be a dial-in conference call facility for
the 9:00 AM GMT (4:00 AM EDT) presentation; dial-in details are as follows:
UK: 0808 100 5150
US/International: +44 208 974 7900
Access Code (to be quoted): 'Analyst Call'
A recording of the presentation will be accessible through each of General
Electric's and Amersham's web sites.
An interview with Sir William Castell in video/audio and text is available on:
http//www.amersham.com and on http//www.cantos.com.
General Electric's third quarter 2003 earnings presentation will be presented at
1:30 PM GMT (8:30 AM EDT) through a web-casting facility which can be accessed
on General Electric's web site at www.ge.com. For persons unable to access the
webcast, dial-in details are as follows:
US: +1 877 810 2615
UK/International: +1 617 786 8334
Access Code: 29085584
Enquiries:
General Electric Company
Richard Wacker (GE Investor Relations) +1 203 373 2468
Pam Wickham (GE Medical Systems) +1 262 544 3530
Louise Binns (GE Corporate Europe) +32 2 235 6912
Peter Stack (GE Corporate Financial) +1 203 373 2283
GE Investments, Inc.
Richard Wacker (GE Investor Relations) +1 203 373 2468
Goldman Sachs International
Simon Dingemans +44 20 7774 1000
Richard Butland +44 20 7774 1000
Tulchan Communications
Andrew Grant +44 20 7353 4200
Amersham plc
Alexandra Morris (Investor Relations) +44 1494 542 051
Dr Lynne Gailey (Media Relations) +44 1494 542 050
Dr Graeme Holland (Media Relations) +44 1494 542 115
Nancy Thingstad (Media Relations, Norway) +44 1494 542 141
JPMorgan
Bernard Taylor +44 20 7742 4000
Julian Oakley +44 20 7742 4000
Edward Banks +44 20 7742 4000
Morgan Stanley
Michael Tory +44 20 7425 5000
Johannes Groeller +44 20 7425 5000
Brunswick
Louise Charlton +44 20 7396 5373
Jon Coles +44 20 7404 5959
Financial Dynamics
David Yates +44 7788 14 4459
Jonathan Birt +44 7884 23 8952
The availability of the Acquisition to persons who are not resident in the
United Kingdom, Norway or the United States may be affected by the laws of the
relevant jurisdictions in which they are located. Persons who are not resident
in the United Kingdom, Norway or the United States should inform themselves of,
and observe, any applicable requirements.
Unless otherwise determined by GE and permitted by applicable law and
regulation, copies of this announcement and any other documents related to the
Acquisition are not being, and must not be, mailed or otherwise forwarded,
distributed or sent in or into Japan or Australia and persons receiving such
documents (including custodians, nominees and trustees) must not distribute or
send them in, into or from Japan or Australia. If the Acquisition is
implemented by way of an Offer (unless otherwise determined by GE and permitted
by applicable law and regulation), the Offer will not be made, directly or
indirectly, in or into, or by use of the mails of, or by any means or
instrumentality (including, without limitation, telephonically or
electronically) of interstate or foreign commerce of, or of any facility of a
national securities exchange of, nor will it be made in or into Canada, Japan or
Australia and the Offer will not be capable of acceptance by any such use,
means, instrumentality or facilities. An offer is not being made in the United
States or Norway by means of this announcement.
This announcement (and oral statements made regarding the Acquisition, including
on the joint analysts and investors presentation announced herein) and other
information published by GE and Amersham contain forward looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Forward looking statements may be identified by words such as 'expects', '
anticipates', 'intends', 'plans', 'believes', 'seeks', 'estimates', 'will' or
words of similar meaning and include, but are not limited to, statements about
the expected future business and financial performance of GE resulting from and
following the Acquisition. These statements are based on management's current
expectations and are inherently subject to uncertainties and changes in
circumstances. Among the factors that could cause actual results to differ
materially from those described in the forward looking statements are factors
relating to satisfaction of the Pre-Conditions and the Conditions, GE's ability
to successfully combine the businesses of GE Medical and Amersham and to realise
expected synergies from the Acquisition, and changes in global, political,
economic, business, competitive, market and regulatory forces. More detailed
information about certain of these factors is contained in GE's and Amersham's
filings with the SEC. Neither GE nor Amersham undertakes any obligations to
update the forward looking statements to reflect actual results, or any change
in events, conditions, assumptions or other factors.
This announcement does not constitute an offer for sale of any securities or an
offer or an invitation to purchase any such securities. If and when GE
commences its Acquisition for Amersham Securities and the Acquisition is
implemented by way of a Scheme, any securities to be issued pursuant to the
Scheme will not be registered under the Securities Act but will be issued in
reliance on the exemption provided by Section 3(a)(10) thereof and Amersham will
furnish the Acquisition Document to the SEC under cover of a Form 6-K. If and
when GE commences its Acquisitions for Amersham Securities and the Acquisition
is implemented by way of an Offer rather than a Scheme, General Electric will
file a Registration Statement relating to the Offer with the SEC. If General
Electric files a Registration Statement with the SEC, it will contain a
prospectus and other documents relating to the Offer. Such prospectus and other
documents will contain important information about GE, Amersham, the Offer and
related matters. Holders of Amersham Securities who are US persons or who are
located in the United States are urged to read such prospectus (if any) and
other documents that would form part of such Registration Statement if and when
it becomes available before they make any decision with respect to the Offer.
Holders of Amersham Securities should also read the related solicitation/
recommendation statement on Schedule 14D-9 that will be filed with the SEC by
Amersham relating to the Offer. Such prospectus and any other relevant
documents filed by General Electric and Amersham with the SEC will be available
free of charge at the SEC's web site at www.sec.gov and from General Electric.
These documents will also be available for inspection and copying at the public
reference room maintained by the SEC at 450 Fifth Street, N.W., Washington, D.C.
20549, US. For further information about the public reference room, call the
SEC at +1 800 732 0330.
The contents of this announcement insofar as it relates to Amersham, the
Amersham Group and the directors of Amersham have been approved by JPMorgan and
Morgan Stanley while the remainder of the contents have been approved by Goldman
Sachs, in each case solely for the purposes of section 21(2)(b) of the Financial
Services and Markets Act 2000.
Goldman Sachs, which is regulated in the United Kingdom by the Financial
Services Authority, is acting exclusively for GE and no one else in connection
with the Acquisition and will not be responsible to anyone other than GE for
providing the protections afforded to customers of Goldman Sachs nor for
providing advice in relation to the Acquisition, or any matter referred to
herein.
JPMorgan, which is regulated in the United Kingdom by the Financial Services
Authority, is acting exclusively for Amersham as joint financial adviser and no
one else in connection with the Acquisition and will not be responsible to
anyone other than Amersham for providing the protections afforded to customers
of JPMorgan nor for providing advice in relation to the Acquisition, or any
matter referred to herein.
Morgan Stanley, which is regulated in the United Kingdom by the Financial
Services Authority, is acting exclusively for Amersham as joint financial
adviser and for no one else in connection with the Acquisition and will not
regard any other person as a client in relation to the Acquisition and will not
be responsible to anyone other than Amersham for providing the protections
afforded to customers of Morgan Stanley nor for providing advice in relation to
the Acquisition, or any matter referred to herein.
Any person who, alone or acting together with any other person(s) pursuant to an
agreement or understanding (whether formal or informal) to acquire or control
securities of General Electric or of Amersham, owns or controls, or becomes the
owner or controller, directly or indirectly, of one per cent. or more of any
class of securities of General Electric or Amersham is generally required under
the provisions of Rule 8 of the City Code to notify a Regulatory Information
Service as specified in the Listing Rules and the Panel by not later than 12:00
noon (London time) on the London business day following the date of the
transaction of every dealing in such securities during the period to the date on
which the Scheme becomes effective (or, if applicable, the Offer becomes or is
declared unconditional as to acceptances or lapses or is otherwise withdrawn).
Dealings by GE or by Amersham or by their respective 'associates' (within the
definition set out in the City Code) in any class of securities of General
Electric or Amersham until the end of such period must also be disclosed.
Please consult your financial adviser immediately if you believe this Rule may
be applicable to you.
GE Amersham
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA OR JAPAN.
NOT FOR RELEASE UNTIL 7:00 AM GMT ON 10 OCTOBER 2003
Recommended share exchange acquisition
by
General Electric Company and GE Investments, Inc.
of
Amersham plc
1. Introduction
GE and Amersham announce their agreement on the terms of a recommended share
exchange acquisition by GE of Amersham. The making of the Acquisition is
subject to the satisfaction or waiver of certain Pre-Conditions and is expected
to be effected by means of a scheme of arrangement under section 425 of the
Companies Act.
Applying the Exchange Ratio on the basis of the Sterling GE Price at
Announcement of £18.32, Amersham Shareholders would be entitled to 0.4367 New GE
Shares for every Amersham Share held. On this basis, the terms of the
Acquisition value each Amersham Share at 800 pence and the diluted share capital
of Amersham at approximately £5.7 billion ($9.5 billion).
These terms represent a premium of approximately 45 per cent. over the price of
an Amersham Share of 552 pence as at the close of business on 7 October 2003,
the last trading day prior to the announcement by Amersham that it had received
an approach.
The Amersham Board, which has been so advised by JPMorgan and Morgan Stanley,
considers the terms of the Acquisition to be fair and reasonable. In providing
advice to the Amersham Board, JPMorgan and Morgan Stanley have taken into
account the commercial assessment of the Amersham Board. Accordingly, the
Amersham Board intends unanimously to recommend that Amersham Shareholders vote
in favour of the Scheme (or, if applicable, accept the Offer) as the directors
of Amersham have undertaken to do in respect of their own respective beneficial
holdings of Amersham Shares (representing, in aggregate, approximately 0.05 per
cent. of the Amersham Shares currently in issue).
The sources and bases of information contained in this announcement are set out
in Appendix IV and the definitions of certain expressions used in this
announcement are contained in Appendix V.
2. The Acquisition
Under the Scheme, and subject to the Pre-Conditions and Conditions and further
terms set out in Appendix II and the full terms and conditions that will be set
out in the Acquisition Document, Amersham Shareholders and holders of Amersham
ADSs will be offered New GE Shares on the following basis:
for each Amersham Share, a number of New GE Shares as determined by the Exchange
Ratio at Completion, such number not to exceed 0.5571
for each Amersham ADS, a number of New GE Shares as determined by the ADS
Exchange Ratio at Completion, such number not to exceed 2.7855
The Exchange Ratio will be calculated as set out in Section 3 below.
Applying the Exchange Ratio on the basis of the Sterling GE Price at
Announcement of £18.32, Amersham Shareholders would be entitled to 0.4367 New GE
Shares for every Amersham Share held, valuing each Amersham Share at 800 pence.
Applying the ADS Exchange Ratio on the basis of the Sterling GE Price at
Announcement of £18.32, holders of Amersham ADSs would be entitled to 2.1835 New
GE Shares for every Amersham ADS held, valuing each Amersham ADS at £40.00.
At Amersham's request, GE has agreed to offer a dealing facility to Amersham
Shareholders who own 5,000 or less Amersham Shares under which the New GE Shares
to which such shareholders become entitled may be sold for their benefit at GE's
cost and under which such shareholders would accordingly receive the gross sale
proceeds. Details of such facility will be included in the Acquisition Document.
If the Scheme had become effective today, it would result in the delivery
pursuant to the Acquisition of up to 307.1 million New GE Shares (being 313.5
million on a diluted basis), representing approximately 3 per cent. of the
issued share capital of General Electric as enlarged by the Acquisition. On the
basis of the Maximum Exchange Ratio, the Scheme would result in the delivery of
391.7 million New GE Shares (being 399.9 million on a diluted basis).
No fractions of New GE Shares will be issued to holders of Amersham Securities.
Fractional entitlements to New GE Shares will be aggregated and sold in the
market and the net proceeds of sale distributed pro rata to the holders of
Amersham Securities entitled to them.
GE Shares are listed on the New York Stock Exchange and also have been admitted
to the Official List of the UK Listing Authority and to trading on the London
Stock Exchange. To the extent necessary, applications will be made for the New
GE Shares to be listed on the New York Stock Exchange and to the UK Listing
Authority for the New GE Shares to be admitted to the Official List of the UK
Listing Authority and to the London Stock Exchange for the New GE Shares to be
admitted to trading on its market for listed securities. No application will be
made to list the New GE Shares on the Oslo Stock Exchange.
3. Exchange Ratio Mechanism
The Exchange Ratio, representing the number of New GE Shares for each Amersham
Share (rounded down to four decimal places), will be finally determined at
Completion. The Exchange Ratio is subject to certain adjustments depending on
the movements in the Sterling GE Price up to the Completion Date and will be
established on the following basis:
• The Acquisition Document will include an Exchange Ratio using a Sterling
GE Price calculated on the basis of the average of the daily volume weighted
average price of a GE Share on the NYSE for the period of ten consecutive
trading days preceding, but not including, the Posting Date. Each such daily
price will be converted from dollars into sterling at the Bank of England $/£
fix on the relevant day;
• The Exchange Ratio at the Posting Date will be determined by dividing
800 pence by the Sterling GE Price at Posting calculated as above (subject to
the Maximum Exchange Ratio);
• If the Sterling GE Price at Completion has declined relative to the
Sterling GE Price at Announcement, the Exchange Ratio at Completion (if not
already at the Maximum Exchange Ratio) will be increased such that the value of
the New GE Shares at Completion remains 800 pence per Amersham Share, save that
in no circumstances shall GE deliver more than the Maximum Exchange Ratio of
0.5571 New GE Shares per Amersham Share. The Maximum Exchange Ratio will be
reached if the Sterling GE Price at Completion declines to £14.36, which is 21.6
per cent. lower than the Sterling GE Price at Announcement; and
• If the Sterling GE Price at Completion has increased relative to the
Sterling GE Price at Posting (the period between Posting and Completion is
expected to be approximately 6 weeks), the Exchange Ratio at Posting will remain
fixed until the amount determined by multiplying that Exchange Ratio by the
Sterling GE Price at Completion exceeds 808 pence. If this amount exceeds 808
pence, the Exchange Ratio will be reduced proportionately such that the value,
based on the Sterling GE Price at Completion, of the number of New GE Shares to
be delivered under the Exchange Ratio continues to equal 808 pence per Amersham
Share.
The ADS Exchange Ratio will be calculated by multiplying the Exchange Ratio
(calculated as described above) by five.
If a dividend has been declared on the GE Shares and the ex-dividend date falls
on a day within the ten trading day period in which the Sterling GE Price at
Completion is calculated (such that trading is both 'cum' and 'ex' dividend
during such calculation period), Amersham Shareholders will receive a cash
amount equal to the amount of such dividend multiplied by the percentage of cum
dividend days included in the ten trading days used to determine the Exchange
Ratio.
GE and Amersham have agreed in the Implementation Agreement that if any changes
are made to General Electric's or Amersham's share capital or any extraordinary
dividends are paid by General Electric or Amersham after the date of this
announcement and before Completion, such adjustments as are necessary will be
made to the Maximum Exchange Ratio and the Exchange Ratio as Goldman Sachs,
JPMorgan and Morgan Stanley agree are fair and reasonable such that the Exchange
Ratio mechanism and the Maximum Exchange Ratio are replicated by reference to
the GE Share price or Amersham Share price (as the case may be) as affected by
the relevant change in share capital or extraordinary dividend.
4. Dividends
Amersham Shareholders will be entitled to any dividends declared or paid by
Amersham in respect of any completed six-month period ended 30 June or 31
December before the Effective Date (or, if applicable, before the date on which
the Offer becomes or is declared unconditional in all respects). Amersham has
agreed to certain limits on the amount of dividends it can declare or pay.
These limits are set out in Appendix III.
GE may elect to pay cash consideration in lieu of any dividend otherwise payable
by Amersham. Should it do so, the amount payable will be increased to take
account of the fact that any such cash consideration will not have attached to
it the tax credit available to individual UK tax resident Amersham Shareholders
on dividend payments. If such cash consideration is paid after the date on which
the dividend would otherwise have been payable, GE will also compensate Amersham
Shareholders for the delay.
New GE Shares will rank pari passu for any dividend declared or paid by General
Electric on or after the Effective Date (or, if applicable, after the date on
which the Offer becomes or is declared unconditional in all respects).
5. Information on Amersham
Amersham, headquartered in the UK, is a global leader in medical diagnostics and
life sciences. The Amersham Group employs over 10,000 people worldwide and had
sales of £1.6 billion ($2.4 billion) in 2002. The Amersham Group was formed in
1997 through the mergers of Amersham International (UK), Pharmacia Biotech
(Sweden) and Nycomed (Norway).
Amersham has three main business areas: medical diagnostics, operating as
Amersham Health, and protein separations and discovery systems, together
operating as Amersham Biosciences.
• Amersham Health (59 per cent. of total Amersham sales in 2002) develops,
manufactures and distributes diagnostic imaging agents and radio-pharmaceuticals
for all imaging modalities that are used in medical imaging procedures. These
diagnostic agents enhance and enable the imaging of anatomy, organs, tissue and
cells to assist with the early detection, diagnosis and management of diseases.
Key products include the imaging agents OmnipaqueTM, MyoviewTM, OmniscanTM and
VisipaqueTM;
• Protein separations (17 per cent. of total Amersham sales in 2002)
develops, manufactures and distributes chromatography purification systems,
membrane products and reagents that are used in the development and manufacture
of biopharmaceuticals and for the laboratory scale separation of proteins for
research and drug development; and
• Discovery systems (24 per cent. of total Amersham sales in 2002)
develops, manufactures and distributes instruments, reagents and software that
are used for drug discovery, research and development with applications
including protein and DNA analysis for genomics and proteomics, cellular
screening and bioassays.
For the financial year ended 31 December 2002, Amersham reported sales of £1.6
billion ($2.4 billion) and net income of £179 million ($269 million). For the
six-month period ended 30 June 2003, Amersham reported sales of £808 million
($1.3 billion) and net income of £45 million ($72 million). As at 31 December
2002, Amersham had net assets of £1.2 billion ($1.9 billion) (at 30 June 2003:
£1.2 billion ($2.0 billion)).
6. Information on General Electric and GE Investments
General Electric, headquartered in the United States, is a diversified
technology and services company dedicated to creating products that make life
better from aircraft engines and power generation to financial services, medical
imaging, television broadcasting and plastics. General Electric operates in
more than 100 countries and employs more than 315,000 people worldwide,
including approximately 75,000 in Europe.
GE Medical is a global leader in diagnostic imaging, healthcare services and
information technology. Its offerings include networking and productivity
tools, clinical information systems, patient monitoring systems, surgery and
vascular imaging, conventional and digital X-ray, computed tomography, electron
beam computed tomography, magnetic resonance, ultrasound and bone mineral
densitometry, positron emission tomography, nuclear medicine and a full line of
clinical and business services. For more than 100 years, health-care providers
worldwide have relied on GE Medical for high quality medical technology and
productivity solutions. GE Medical operates in more than 100 countries and
employs more than 30,000 people worldwide. For the financial year ended 31
December 2002, GE Medical reported sales of $9.0 billion (£6.0 billion) and
operating profit of $1.5 billion (£1.0 billion). For the six-month period ended
30 June 2003, GE Medical reported revenues of $4.5 billion (£2.8 billion) and
operating profit of $746 million (£463 million).
GE Investments, headquartered in the United States, is one of General Electric's
US subsidiaries. GE Investments has direct and indirect ownership of various
subsidiaries in the GE Group which have interests in several leading businesses
of the GE Group, such as insurance, aircraft engines, industrial systems,
lighting, appliances, speciality chemicals and information technology.
For the year ended 31 December 2002, General Electric reported sales of $132
billion (£88 billion) and net income of $14.1 billion (£9.4 billion). For the
six-month period ended 30 June 2003, General Electric reported sales of $64
billion (£40 billion) and net income of $6.8 billion (£4.2 billion). As at 31
December 2002, General Electric had total assets of $575 billion (£357 billion)
and as at 30 June 2003 $615 billion (£373 billion). As at 9 October 2003,
General Electric had a market capitalisation of approximately $302.5 billion
(£182.3 billion).
Further information on General Electric is available on its web site at
www.ge.com.
General Electric's third quarter 2003 earnings presentation will be presented at
1:30 p.m. (London time) (8:30 a.m., New York time) through a web-casting
facility which can be accessed on its web site.
7. Background to and Reasons for the Acquisition
GE's acquisition of Amersham strongly fits with the GE Group's overall strategy
for growth. The GE Group's ongoing strategy centres on five key growth
initiatives:
• Building on the GE Group's commitment to Technological Excellence to
expand margins and build its installed base of products;
• Providing Services for the customers of the GE Group to improve returns,
competitiveness and customer satisfaction;
• Enduring Customer Relationships that help customers and the GE Group win
together over the long term;
• Continuing Globalisation of the GE Group's activities to accelerate
growth and increase competitiveness - tapping new markets, new sources of supply
and new intellectual capital - hiring the very best people from all around the
world; and
• Allocating Capital in businesses and markets that can increase growth
and provide higher returns. The GE Group not only grows by acquiring businesses
but more importantly by growing the businesses it acquires.
The acquisition of Amersham, a global leader in diagnostic imaging agents and in
life sciences, significantly advances General Electric's strategy of addressing
high-growth, high-technology segments of the global healthcare industry.
Amersham's imaging agents and biosciences businesses will add new,
high-technology platforms to GE Medical's diagnostic imaging, healthcare
services and information technology businesses, positioning GE Medical to
participate in exciting new developments in molecular imaging and personalised
medicine. Through the combination of skills in imaging, engineering, biology,
chemistry and instrumentation the combined companies will be able to take the
knowledge being generated in gene and protein research directly into diagnosis.
This will enable GE Medical to accelerate the development of molecular imaging
and personalised medicine, where it will be possible to predict, prevent and
treat disease with therapies tailored to the individual.
General Electric's management believes the Acquisition will:
• Position General Electric for a new chapter in medicine by creating a
healthcare company with broad expertise in imaging, diagnostic pharmaceuticals
and drug discovery;
• Create a group of technology and service driven healthcare businesses
which will have combined 2003 pro forma revenues in excess of $13 billion;
• Accelerate the development of molecular imaging and personalised
medicine by more rapidly developing and bringing to market new targeted imaging
agents and diagnostics that will enable our customers to diagnose, treat and
monitor diseases at an earlier stage than ever before;
• Expand the addressable customer base, providing significant new channels
for each company's products and services around the world. For example, General
Electric expects to access new sales channels in the pharmaceutical industry for
GE Medical's imaging technology and services;
• Perform financially for investors. The combination of Amersham and GE
Medical is expected by General Electric to be non-dilutive to 2004 earnings per
share (before in-process research and development charges) and $0.01 accretive
in 2005. General Electric expects to generate revenue synergies by the end of
the third full year in the order of $350 million to $400 million per annum,
which are expected to translate into operating profit synergy benefits of $100
million to $200 million per annum. General Electric expects the revenue
synergies to be achieved through a variety of means, including access to new
channels for each company's products and services, channel efficiencies,
accelerated global expansion and new product introductions. Similarly, General
Electric expects to achieve cost synergies from the combined business in the
range of $300 million to $400 million per annum by the end of the third full
year, an amount that represents approximately 3 per cent. of the combined
businesses' total cost base. General Electric expects these cost synergies to
be achieved through a variety of means including improved sourcing, reduced
general and administration and global infrastructure costs and operating
efficiencies across the combined businesses. General Electric expects
approximately half of these revenue and cost synergies to be achieved by the end
of the first full year following the Acquisition*; and
• Strengthen General Electric's capital base and AAA credit rating through
the issuance of General Electric stock, while maximising flexibility to fund
future growth.
* The foregoing statements as to financial accretion are not intended to mean
that General Electric earnings or earnings per share for any period will
necessarily exceed those of any prior year.
8. Business Leadership
Upon completion of the Acquisition, Sir William Castell will become a Vice
Chairman and member of the Board of Directors of General Electric and, as CEO of
GE Healthcare Technologies, will have financial and leadership responsibility
for GE Healthcare Technologies, the combined Amersham and GE Medical businesses.
Sir William Castell will also lead the integration process to deliver the
expected operating synergies. Joseph Hogan, Senior Vice President of General
Electric, will continue to lead the GE Medical business. The GE Healthcare
Technologies business will be based with Sir William Castell in the UK.
9. Undertakings by the Directors of Amersham
Undertakings to vote in favour of the Scheme (or, if applicable, accept the
Offer) have been received by GE from the directors of Amersham who hold Amersham
Shares amounting, in aggregate, to 361,537 Amersham Shares (representing 0.05
per cent. of the issued share capital of Amersham). Such undertakings will cease
to be binding if the Amersham Board withdraws its recommendation of the
Acquisition.
10. Management and Employees
GE attaches great importance to the skills and experience of the existing
management and employees of the Amersham Group and believes that they will
benefit from the greater opportunities within the Combined Group. The existing
employment rights, including pension rights, of all management and employees of
the Amersham Group will be fully safeguarded.
11. Amersham Share Schemes
At the same time as the publication of the Acquisition Document, explanatory
letters will be sent to the participants in the Amersham Share Schemes
explaining the effect of the Scheme on them and, where applicable, their right
to exercise share options or to receive shares under awards.
As the Scheme will apply only to Amersham Shares in issue at the Record Date, it
is proposed to amend the articles of association of Amersham at the
Extraordinary General Meeting to provide that, if the Scheme becomes effective,
any Amersham Shares issued after the Record Date will automatically (and
immediately following issue) be transferred to GE in exchange for New GE Shares
on the same basis as under the Scheme. Consequently, participants in the
Amersham Share Schemes who exercise any options or receive shares under awards
after the Scheme becomes effective will receive New GE Shares in the same ratio
as under the Scheme.
In addition, holders of options under the Amersham Share Schemes will be given
the opportunity to release their share options in return for a payment equal to
the difference between the option exercise price and the cash value of the New
GE Shares delivered pursuant to the terms of the Acquisition as at the
Completion Date. Further details of these proposals will be set out in the
letters to the participants in the Amersham Share Schemes.
12. Structure of the Acquisition
The Acquisition is expected to be effected, once the Pre-Conditions have been
satisfied or waived, by means of a scheme of arrangement between Amersham and
its shareholders under section 425 of the Companies Act. The procedure involves
an application by Amersham to the Court to sanction the Scheme and confirm the
cancellation of all the scheme shares (generally the Amersham Shares at the
Record Date), in consideration for which the Amersham Shareholders will receive
New GE Shares on the basis set out above.
Before the Final Court Order can be sought, the Scheme will require approval by
Amersham Shareholders at a Court convened meeting and approval of the Amersham
Shareholders of certain resolutions to be proposed at the Extraordinary General
Meeting.
The Court Meeting will be convened by order of the Court for the purposes of
considering and, if thought fit, approving the Scheme (with or without
modification). The Scheme will be approved at the Court Meeting if a majority
in number representing not less than 75 per cent. in value of the Amersham
Shareholders present and voting, either in person or by proxy, votes in favour
of the Scheme.
The Extraordinary General Meeting will be convened for the purposes of
considering and, if thought fit, passing a special resolution to approve the
reduction of Amersham's share capital and amendments to the articles of
association of Amersham necessary to implement the Scheme and any other
resolutions that may be necessary.
Once the necessary approvals from the Amersham Shareholders have been obtained
and the other Conditions have been satisfied or (where applicable) waived, the
Scheme will become effective upon sanction by the Court and registration of the
Final Court Order by the Registrar of Companies in England and Wales.
It is intended that, following the Acquisition becoming effective (or, if
applicable, becoming or being declared unconditional in all respects), and
subject to applicable requirements of the London, New York and Oslo Stock
Exchanges, GE will procure that Amersham will apply to those exchanges for the
Amersham Securities to cease trading and to the UK Listing Authority to remove
the Amersham Shares from the Official List.
GE and Amersham have agreed that, if GE so elects, the Acquisition may be
implemented by way of an Offer. In this event, the Offer will be implemented on
the same terms, so far as applicable, as those which would apply to the Scheme.
If GE does elect to implement the Acquisition by way of an Offer, and if
sufficient acceptances of the Offer are received and/or sufficient Amersham
Shares and Amersham ADSs are otherwise acquired, it is the intention of GE to
apply the provisions of sections 428 to 430F (inclusive) of the Companies Act to
acquire compulsorily any outstanding Amersham Shares (including Amersham Shares
represented by Amersham ADSs) to which the Offer relates.
General Electric and GE Investments, who are to acquire Amersham jointly under
the Acquisition, reserve the right to acquire Amersham jointly with one or more
other subsidiaries of the GE Group in such proportions as may be agreed. If the
acquisition is made with such further subsidiaries, all references to GE as the
joint offerors in this announcement should be read as references to GE and such
further subsidiaries where the context requires.
13. Implementation Agreement
GE and Amersham have entered into an agreement regarding the implementation of
the Scheme (or, if applicable, the Offer) and the conduct of the business of the
Amersham Group in the period up to the Effective Date (or, if applicable, the
date on which the Offer becomes or is declared unconditional in all respects).
Under the Implementation Agreement, a payment may become due to either GE or
Amersham in certain circumstances.
The Pre-Conditions allow GE, in the period up to the satisfaction or waiver of
the Regulatory Pre-Conditions, not to proceed with the Acquisition if Amersham
breaches certain covenants in the Implementation Agreement (described in more
detail in Appendix III). Note 2 on Rule 13 of the City Code, which restricts
the ability of an offeror to lapse an offer except where the Panel agrees that
the circumstances allowing a condition to be invoked are of material
significance to the offeror in the context of the offer, will not apply.
Following the satisfaction or waiver of the Regulatory Pre-Conditions, Note 2 on
Rule 13 of the City Code will also not apply in respect of breaches of certain
of the covenants referred to above in so far as they may be relevant to an
invocation of Condition (n) as more fully described in Appendix III, but will
apply in all other respects.
A summary of certain provisions of the Implementation Agreement is set out in
Appendix III.
14. Disclosure of interests in Amersham
As at 9 October 2003, the last trading day prior to this announcement, GE
Pension Fund held 131,614 Amersham Shares.
Save as disclosed above, as at 9 October 2003, the last trading day prior to
this announcement, neither GE, nor any of the directors of GE, nor their close
relatives and related trusts, nor, so far as GE is aware, any party acting in
concert with GE, owned or controlled any Amersham Securities or held any options
to purchase Amersham Securities or had entered into any derivative referenced to
Amersham Securities. In the interests of confidentiality, GE has not made
enquiries in this respect of certain parties who may be presumed by the Panel to
be acting in concert with it for the purposes of the Acquisition.
15. Regulation
The Acquisition and the posting of the Acquisition Document are subject to
satisfaction or waiver of the Regulatory Pre-Conditions, relating to the
obtaining of regulatory clearances from the European Commission and the United
States competition authorities. GE and Amersham intend to proceed with the
Acquisition through despatching the formal Acquisition Document as soon as
practicable after satisfaction or waiver of the Pre-Conditions. The necessary
clearances are expected to be obtained within the first half of 2004. If the
Pre-Conditions have not been satisfied or waived by 10 October 2004, or such
later date as GE may (with the approval of the Panel and, for so long as the
Acquisition remains recommended and no Competing Proposal has been announced,
Amersham) determine, the Acquisition will not proceed.
16. General
The Acquisition will comply with the applicable rules and regulations of the UK
Listing Authority, the London Stock Exchange and the City Code. The Acquisition
will be governed by English law and will be subject to the jurisdiction of the
English courts and the Conditions and further terms set out in Appendix II, and
the full terms and conditions to be set out in the Acquisition Document. In
addition, the Acquisition is subject to the applicable requirements of the
United States federal and state securities laws and the applicable rules and
regulations of the New York Stock Exchange (except to the extent exempt from
such requirements) as well as applicable Norwegian rules and regulations.
The timetable for the Acquisition will be as approved by the Panel but will also
be subject to certain requirements of the SEC. Further details will be
contained in the Acquisition Document.
In accordance with Rule 2.10 of the City Code, as at 9 October 2003, 703,135,827
Amersham Shares were in issue. The International Securities Identification
Number for Amersham Shares is GB0002747532 and for Amersham ADSs is
US0307191082. In addition, as at 26 September 2003, the most recent available
date, 10,040,860,127 GE Shares were in issue. The International Securities
Identification Number for GE Shares is US3696041033.
GE has been advised by Goldman Sachs. Amersham has been advised jointly by
JPMorgan and Morgan Stanley.
Definitions of certain expressions used in this announcement are set out in
Appendix V.
17. Recommendation
The Amersham Board, which has been so advised by JPMorgan and Morgan Stanley,
considers the terms of the Acquisition to be fair and reasonable. In providing
advice to the Amersham Board, JPMorgan and Morgan Stanley have taken into
account the commercial assessment of the Amersham Board. Accordingly, the
Amersham Board intends unanimously to recommend that Amersham Shareholders vote
in favour of the Scheme (or, if applicable, accept the Offer) as the directors
of Amersham have undertaken to do in respect of their own respective beneficial
holdings of Amersham Shares (representing, in aggregate, approximately 0.05 per
cent. of the Amersham Shares currently in issue).
Enquiries:
General Electric Company
Richard Wacker (GE Investor Relations) +1 203 373 2468
Pam Wickham (GE Medical Systems) +1 262 544 3530
Louise Binns (GE Corporate Europe) +32 2 235 6912
Peter Stack (GE Corporate Financial) +1 203 373 2283
GE Investments, Inc.
Richard Wacker (GE Investor Relations) +1 203 373 2468
Goldman Sachs International
Simon Dingemans +44 20 7774 1000
Richard Butland +44 20 7774 1000
Tulchan Communications
Andrew Grant +44 20 7353 4200
Amersham plc
Alexandra Morris (Investor Relations) + 44 1494 542 051
Dr Lynne Gailey (Media Relations) + 44 1494 542 050
Dr Graeme Holland (Media Relations) + 44 1494 542 115
Nancy Thingstad (Media Relations, Norway) + 44 1494 542 141
JPMorgan
Bernard Taylor +44 20 7742 4000
Julian Oakley +44 20 7742 4000
Edward Banks +44 20 7742 4000
Morgan Stanley
Michael Tory +44 20 7425 5000
Johannes Groeller +44 20 7425 5000
Brunswick
Louise Charlton +44 20 7396 5373
Jon Coles +44 20 7404 5959
Financial Dynamics
David Yates +44 7788 14 4459
Jonathan Birt +44 7884 23 8952
The availability of the Acquisition to persons who are not resident in the
United Kingdom, Norway or the United States may be affected by the laws of the
relevant jurisdictions in which they are located. Persons who are not resident
in the United Kingdom, Norway or the United States should inform themselves of,
and observe, any applicable requirements.
Unless otherwise determined by GE and permitted by applicable law and
regulation, copies of this announcement and any other documents related to the
Acquisition are not being, and must not be, mailed or otherwise forwarded,
distributed or sent in or into Japan or Australia and persons receiving such
documents (including custodians, nominees and trustees) must not distribute or
send them in, into or from Japan or Australia. If the Acquisition is
implemented by way of an Offer (unless otherwise determined by GE and permitted
by applicable law and regulation), the Offer will not be made, directly or
indirectly, in or into, or by use of the mails of, or by any means or
instrumentality (including, without limitation, telephonically or
electronically) of interstate or foreign commerce of, or of any facility of a
national securities exchange of, nor will it be made in or into Canada, Japan or
Australia and the Offer will not be capable of acceptance by any such use,
means, instrumentality or facilities. An offer is not being made in the United
States or Norway by means of this announcement.
This announcement (and oral statements made regarding the Acquisition, including
on the joint analysts and investors presentation announced herein) and other
information published by GE and Amersham contain forward looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Forward looking statements may be identified by words such as 'expects', '
anticipates', 'intends', 'plans', 'believes', 'seeks', 'estimates', 'will' or
words of similar meaning and include, but are not limited to, statements about
the expected future business and financial performance of GE resulting from and
following the Acquisition. These statements are based on management's current
expectations and are inherently subject to uncertainties and changes in
circumstances. Among the factors that could cause actual results to differ
materially from those described in the forward looking statements are factors
relating to satisfaction of the Pre-Conditions and the Conditions, GE's ability
to successfully combine the businesses of GE Medical and Amersham and to realise
expected synergies from the Acquisition, and changes in global, political,
economic, business, competitive, market and regulatory forces. More detailed
information about certain of these factors is contained in GE's and Amersham's
filings with the SEC. Neither GE nor Amersham undertakes any obligations to
update the forward looking statements to reflect actual results, or any change
in events, conditions, assumptions or other factors.
This announcement does not constitute an offer for sale of any securities or an
offer or an invitation to purchase any such securities. If and when GE
commences its Acquisition for Amersham Securities and the Acquisition is
implemented by way of a Scheme, any securities to be issued pursuant to the
Scheme will not be registered under the Securities Act but will be issued in
reliance on the exemption provided by Section 3(a)(10) thereof and Amersham will
furnish the Acquisition Document to the SEC under cover of a Form 6-K. If and
when GE commences its Acquisitions for Amersham Securities and the Acquisition
is implemented by way of an Offer rather than a Scheme, General Electric will
file a Registration Statement relating to the Offer with the SEC. If General
Electric files a Registration Statement with the SEC, it will contain a
prospectus and other documents relating to the Offer. Such prospectus and other
documents will contain important information about GE, Amersham, the Offer and
related matters. Holders of Amersham Securities who are US persons or who are
located in the United States are urged to read such prospectus (if any) and
other documents that would form part of such Registration Statement if and when
it becomes available before they make any decision with respect to the Offer.
Holders of Amersham Securities should also read the related solicitation/
recommendation statement on Schedule 14D-9 that will be filed with the SEC by
Amersham relating to the Offer. Such prospectus and any other relevant
documents filed by General Electric and Amersham with the SEC will be available
free of charge at the SEC's web site at www.sec.gov and from General Electric.
These documents will also be available for inspection and copying at the public
reference room maintained by the SEC at 450 Fifth Street, N.W., Washington, D.C.
20549, US. For further information about the public reference room, call the
SEC at +1 800 732 0330.
The contents of this announcement insofar as it relates to Amersham, the
Amersham Group and the directors of Amersham have been approved by JPMorgan and
Morgan Stanley while the remainder of the contents have been approved by Goldman
Sachs, in each case solely for the purposes of section 21(2)(b) of the Financial
Services and Markets Act 2000.
Goldman Sachs, which is regulated in the United Kingdom by the Financial
Services Authority, is acting for GE and no one else in connection with the
Acquisition and will not be responsible to anyone other than GE for providing
the protections afforded to customers of Goldman Sachs nor for providing advice
in relation to the Acquisition, or any matter referred to herein.
JPMorgan, which is regulated in the United Kingdom by the Financial Services
Authority, is acting exclusively for Amersham as joint financial adviser and no
one else in connection with the Acquisition and will not be responsible to
anyone other than Amersham for providing the protections afforded to customers
of JPMorgan nor for providing advice in relation to the Acquisition, or any
matter referred to herein.
Morgan Stanley, which is regulated in the United Kingdom by the Financial
Services Authority, is acting exclusively for Amersham as joint financial
adviser and for no one else in connection with the Acquisition and will not
regard any other person as a client in relation to the Acquisition and will not
be responsible to anyone other than Amersham for providing the protections
afforded to customers of Morgan Stanley nor for providing advice in relation to
the Acquisition, or any matter referred to herein.
Any person who, alone or acting together with any other person(s) pursuant to an
agreement or understanding (whether formal or informal) to acquire or control
securities of General Electric or of Amersham, owns or controls, or becomes the
owner or controller, directly or indirectly, of one per cent. or more of any
class of securities of General Electric or Amersham is generally required under
the provisions of Rule 8 of the City Code to notify a Regulatory Information
Service as specified in the Listing Rules and the Panel by not later than 12:00
noon (London time) on the London business day following the date of the
transaction of every dealing in such securities during the period to the date on
which the Scheme becomes effective (or, if applicable, the Offer becomes or is
declared unconditional as to acceptances or lapses or is otherwise withdrawn).
Dealings by GE or by Amersham or by their respective 'associates' (within the
definition set out in the City Code) in any class of securities of General
Electric or Amersham until the end of such period must also be disclosed.
Please consult your financial adviser immediately if you believe this Rule may
be applicable to you.
APPENDIX I
Pre-Conditions of the Acquisition
The making of the Acquisition, and the posting of the Acquisition Document, are
subject to the following Pre-Conditions being satisfied or waived:
(a) insofar as the Acquisition constitutes a concentration with a
Community dimension within the scope of Council Regulation (EEC) 4064/89 (as
amended) (the 'Merger Regulation'), the European Commission making a decision,
in terms and in a form satisfactory to GE under Article 6(1)(b) or Article 8(2)
of the Merger Regulation (or being deemed to have done so under Article 10(6) of
the Merger Regulation) declaring the proposed acquisition of Amersham by GE
compatible with the common market;
(b) all notifications, filings and applications which are
necessary under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (as
amended) and the regulations thereunder having been made and all or any
appropriate waiting periods (including any extensions thereof), having expired,
lapsed or been terminated (as appropriate) and the United States competition
authorities having determined to take no action, in each case in respect of the
Acquisition or control of Amersham by GE or any member of the GE Group; and
(c) the Implementation Agreement not having been terminated in
accordance with its terms.
Following satisfaction or waiver of the Regulatory Pre-Conditions, Pre-Condition
(c) will cease to apply.
GE reserves the right to waive, in whole or in part, all or any of the
Pre-Conditions. The consent of Amersham will be required to any such waiver,
save if the Amersham Board has withdrawn its recommendation of the Acquisition
or if a Competing Proposal has been announced.
The Acquisition will be made if the Pre-Conditions have been satisfied or waived
by no later than the close of business (New York time) on 10 October 2004, or
such later date as GE may, with the approval of the Panel, determine. The
consent of Amersham will be required to any such extension.
APPENDIX II
Conditions and Further Terms of the Acquisition
Conditions of the Acquisition
The Acquisition which will be made once the Pre-Conditions have been satisfied
or waived, will comply with the applicable rules and regulations of the UK
Listing Authority, the London Stock Exchange and the City Code. The Acquisition
will be governed by English law and will be subject to the jurisdiction of the
English courts and to the terms and conditions set out below and the further
terms to be set out in the Acquisition Document. In addition, the Acquisition is
subject to the applicable requirements of the United States federal and state
securities laws and applicable rules and regulations of the NYSE (except to the
extent exempt from such requirements) as well as the applicable Norwegian rules
and regulations.
1. The Acquisition and the Scheme will be subject to the
following Conditions:
(a) approval of the Scheme by a majority in number, representing
75 per cent. or more in value present and voting, either in person or by proxy,
at the Court Meeting, or at any adjournment of the Court Meeting;
(b) the resolution(s) required to approve and implement the
Scheme being duly passed by the requisite majority at the Extraordinary General
Meeting, or at any adjournment of the Amersham EGM;
(c) sanction (with or without modifications, on terms reasonably
acceptable to GE) of the Scheme and confirmation of the reduction of capital
involved therein by the Court and an office copy of the order of the Court
sanctioning the Scheme and confirming the reduction of capital involved in the
Scheme being delivered for registration to the Registrar of Companies in England
and Wales and being registered by him;
(d) in the event that Pre-Condition (a) is waived, insofar as the
Acquisition constitutes a concentration with a Community dimension within the
scope of Council Regulation (EEC) 4064/89 (as amended) (the 'Merger Regulation'),
the European Commission making a decision, in terms and in a form
satisfactory to GE under Article 6(1)(b) or Article 8(2) of the Merger
Regulation (or being deemed to have done so under Article 10(6) of the Merger
Regulation) declaring the proposed acquisition of Amersham by GE compatible with
the common market;
(e) in the event that Pre-Condition (b) is waived, all
notifications, filings and applications which are necessary under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976 (as amended) and the
regulations thereunder having been made and all or any appropriate waiting
periods (including any extensions thereof), having expired, lapsed or been
terminated (as appropriate) and the United States competition authorities having
determined to take no action, in each case in respect of the Acquisition or
control of Amersham by GE or any member of the GE Group;
(f) (i) the approval for listing on the NYSE, subject to
official notice of issue, of the New GE Shares; and
(ii) admission of the New GE Shares to listing on the Official
List and to trading on the London Stock Exchange's market for listed securities
becoming effective (or, if GE so determines and subject to the consent of the
Panel, the UK Listing Authority and the London Stock Exchange agreeing to admit
such shares to listing and trading respectively);
(g) (i) all necessary notifications, filings or applications
having been made in connection with the Acquisition and all statutory or
regulatory obligations in any jurisdiction having been complied with in
connection with the Acquisition or the acquisition or proposed acquisition by
any member of the Wider GE Group of any shares or other securities (or the
equivalent) in, or control of, Amersham by GE or any member of the Wider GE
Group;
(ii) all authorisations, orders, recognitions, grants, consents,
licences, confirmations, clearances, permissions and approvals (collectively '
Consent') deemed necessary by GE for or in respect of the Acquisition or the
acquisition or the proposed acquisition of any shares or other securities (or
the equivalent) in, or control of, Amersham by GE or by any member of the Wider
GE Group having been obtained in terms and in a form satisfactory to GE from all
appropriate Third Parties or persons with whom any member of the Wider Amersham
Group has entered into contractual arrangements; and
(iii) all such Consents together with all Consents necessary to carry on
the business of any member of the Wider Amersham Group having been obtained and
remaining in full force and effect and all filings necessary for such purpose
having been made and there being no notice or intimation of any intention to
revoke, suspend, restrict, modify or not to renew any of the same at the time at
which the Acquisition becomes otherwise unconditional;
(h) there being no provision of any agreement, arrangement,
licence, permit, lease or other instrument to which any member of the Wider
Amersham Group is a party or by or to which any such member or any of its assets
may be bound, entitled or subject, or any circumstance which, in each case as a
consequence of the Acquisition or the acquisition or the proposed acquisition of
any shares or other securities (or the equivalent) in Amersham or of a change in
the control or management of the Wider Amersham Group or otherwise, would or
might reasonably be expected to result in, in any case, to the extent which is
material in the context of the Wider Amersham Group taken as a whole:
(i) any moneys borrowed by or any other indebtedness (actual
or contingent) of, or grant available to any such member, being or becoming
repayable or capable of being declared repayable immediately or earlier than
their or its stated maturity date or repayment date or the ability of any such
member to borrow moneys or incur any indebtedness being withdrawn or inhibited
or being capable of becoming or being withdrawn or inhibited;
(ii) any such agreement, arrangement, licence, permit, lease or
instrument, or the interests or business of any such member in or with, any
person, firm or body (or any agreement or arrangements relating to any such
interest or business) or the rights, liabilities, obligations or interests of
any such member thereunder being terminated or modified or affected or any
onerous obligation or liability arising or any adverse action being taken or
arising thereunder;
(iii) any assets or interests of any such member being or falling
to be disposed of or charged or any right arising under which any such asset or
interest could be required to be disposed of or charged or could cease to be
available to any such member, in each case, other than in the ordinary course of
business;
(iv) the creation or enforcement of any mortgage, charge or other
security interest over the whole or any part of the business, property or assets
of any such member;
(v) the value of any such member or its financial or trading
position being prejudiced or adversely affected;
(vi) any such member ceasing to be able to carry on business
under any name under which it presently does so; or
(vii) the creation of any liability, actual or contingent, by any
such member,
and no event having occurred which, under any provision of any agreement,
arrangement, licence, permit, lease or other instrument to which any member of
the Wider Amersham Group is a party or by or to which any such member or any of
its assets may be bound, entitled or subject, could result in any of the events
or circumstances as are referred to in sub-paragraphs (i) to (vii) inclusive of
this Condition (h);
(i) no Third Party having decided to take, institute, implement
or threaten any action, proceeding, suit, investigation, enquiry or reference,
or having required any action to be taken or otherwise having done anything or
having enacted, made or proposed any statute, regulation, decision or order and
there not continuing to be outstanding any statute, regulation, decision or
order which would or might reasonably be expected, in any case, to an extent
which is material in the context of the Wider GE Group or the Wider Amersham
Group (as the case may be) taken as a whole:
(i) require, prevent or delay the divestiture, or alter the
terms envisaged for any proposed divestiture by any member of the Wider GE Group
or any member of the Wider Amersham Group of all or any portion of their
respective businesses, assets or property or impose any limitation on the
ability of any of them to conduct their respective businesses (or any of them)
or to own any of their respective assets or properties or any part thereof;
(ii) require, prevent or delay the divestiture by any member of
the Wider GE Group of any shares or other securities (or the equivalent) in
Amersham;
(iii) impose any limitation on, or result in a delay in, the
ability of any member of the Wider GE Group or of the Wider Amersham Group,
directly or indirectly, to acquire or to hold or to exercise effectively any
rights of ownership in respect of shares or loans or securities convertible into
shares or any other securities (or the equivalent) in any member of the Wider
Amersham Group or the Wider GE Group or to exercise management control over any
such member;
(iv) otherwise adversely affect the business, assets or profits
of any member of the Wider GE Group or of any member of the Wider Amersham
Group;
(v) make the Acquisition, its implementation or the acquisition
or proposed acquisition by GE or any member of the Wider GE Group of any shares
or other securities (or the equivalent) in, or control of, Amersham void,
illegal, and/or unenforceable in or under the laws of any relevant jurisdiction,
or otherwise, directly or indirectly, restrain, restrict, prohibit, delay or
otherwise interfere with the implementation of, or impose additional conditions
or obligations with respect to, or otherwise challenge or interfere with or
require amendment of, the Acquisition or the acquisition by GE of any shares or
other securities (or the equivalent) of Amersham;
(vi) require any member of the Wider GE Group or the Wider
Amersham Group to offer to acquire any shares or other securities (or the
equivalent) or interest in any member of the Wider Amersham Group (other than
Amersham) or the Wider GE Group owned by any third party;
(vii) impose any limitation on the ability of any member of the
Wider Amersham Group or the Wider GE Group to integrate or co-ordinate its
business, or any part of it, with all or any part of the businesses of any other
member of the Wider Amersham Group and/or the Wider GE Group; or
(viii) result in any member of the Wider Amersham Group ceasing to
be able to carry on business under any name under which it presently does so,
and all applicable waiting and other time periods (including any extensions
thereof) during which any such Third Party could institute, implement or
threaten any action, proceeding, suit, investigation, enquiry or reference or
any other step under the laws of any jurisdiction in respect of the Acquisition
or the acquisition or proposed acquisition of any shares or other securities (or
the equivalent) having expired, lapsed or been terminated;
(j) except as disclosed in the Amersham Annual Report and
Accounts or the Amersham Interim Results or as otherwise publicly announced by
or on behalf of Amersham (by the delivery of an announcement to a Regulatory
Information Service as specified in the Listing Rules) prior to 10 October 2003
or as otherwise fairly disclosed to GE in writing by or on behalf of Amersham
prior to 10 October 2003, no member of the Wider Amersham Group having, since 31
December 2002:
(i) save as between Amersham and wholly-owned subsidiaries of
Amersham or for the Amersham Shares issued pursuant to the exercise of options
granted prior to 10 October 2003 under the Amersham Share Schemes, issued or
agreed to issue, authorised or proposed the issue of additional shares of any
class save to the extent the same is not material in the context of the
Acquisition;
(ii) save as between Amersham and wholly-owned subsidiaries of
Amersham, issued or agreed to issue, authorised or proposed the issue of
securities convertible into shares of any class or rights, warrants or options
to subscribe for, or acquire, any such shares or convertible securities save to
the extent the same is not material in the context of the Acquisition;
(iii) other than to another member of the Amersham Group and save
as provided in the Implementation Agreement, recommended, declared, paid or made
or proposed to recommend, declare, pay or make any bonus, dividend or other
distribution whether payable in cash or otherwise;
(iv) save for intra-Amersham Group transactions, merged with or
demerged from any body corporate or acquired or disposed of or transferred,
mortgaged or charged or created any security interest over or leased or licensed
any assets or any right, title or interest in any asset (including shares and
trade investments) or authorised or proposed or announced any intention to
propose any merger, demerger, acquisition or disposal, transfer, mortgage,
charge, security interest, lease or licence, in each case save in the ordinary
course of business or to the extent the same is not material in the context of
the Wider Amersham Group taken as a whole;
(v) save for intra-Amersham Group transactions, made or
authorised or proposed or announced an intention to propose any change in its
loan capital save to the extent the same is not material in the context of the
Wider Amersham Group taken as a whole;
(vi) save for intra-Amersham Group transactions, issued,
authorised or proposed the issue of any debentures or incurred or increased any
indebtedness or become subject to any guarantee or other contingent liability
save to the extent the same is not material in the context of the Wider Amersham
Group taken as a whole;
(vii) purchased, redeemed or repaid or announced any proposal to
purchase, redeem or repay any of its own shares or other securities or reduced
or, save in respect to the matters mentioned in sub-paragraph (i) above, made
any other change to any part of its share capital save to the extent the same is
not material in the context of the Wider Amersham Group taken as a whole;
(viii) implemented, or authorised, proposed or announced its
intention to implement, any reconstruction, amalgamation, scheme, commitment or
other transaction or arrangement otherwise than in the ordinary course of
business, save to the extent the same is not material in the context of the
Wider Amersham Group taken as a whole, or, save in respect of normal annual
salary increases in accordance with past remuneration policies, entered into or
changed or made any offer (which remains open for acceptance) to enter into or
change the terms of any contract with any director or senior executive;
(ix) entered into or changed or authorised, proposed or announced
its intention to enter into or change any contract, transaction or commitment
(whether in respect of capital expenditure or otherwise) which is of a long
term, onerous or unusual nature or magnitude or which is or might reasonably be
expected to be restrictive on the businesses of any member of the Wider Amersham
Group or the Wider GE Group or which involves or could involve an obligation of
such a nature or magnitude or which is other than in the ordinary course of
business and which, in any case, has a material adverse effect on the Wider
Amersham Group or the Wider GE Group (as the case may be) taken as a whole;
(x) (other than in respect of a member which is dormant and was
solvent at the relevant time) taken any corporate action or had any legal
proceedings started or threatened against it for its winding-up, dissolution or
reorganisation or for the appointment of a receiver, administrative receiver,
administrator, trustee or similar officer of all or any of its assets or
revenues or any analogous proceedings in any jurisdiction or had any such person
appointed save to the extent the same is not material in the context of the
Wider Amersham Group taken as a whole;
(xi) been unable, or admitted in writing that it is unable, to pay
its debts or having stopped or suspended (or threatened to stop or suspend)
payment of its debts generally or ceased or threatened to cease carrying on all
or a substantial part of its business save to the extent the same is not
material in the context of the Wider Amersham Group taken as a whole;
(xii) waived, settled or compromised any claim otherwise than in
the ordinary course of business save to the extent the same is not material in
the context of the Wider Amersham Group taken as a whole;
(xiii) made any alteration to its memorandum or articles of
association or other incorporation documents or, except for any change required
by reason of a concurrent change in applicable law, regulation or generally
accepted accounting practice, to any method of accounting or accounting practice
used by it on 10 October 2003 and which, in any case, is materially adverse in
the context of the Wider Amersham Group taken as a whole;
(xiv) amended the terms (including terms relating to acceleration of
vesting) of any of the Amersham Share Schemes in a manner which is materially
adverse in the context of the Wider Amersham Group taken as whole;
(xv) entered into or varied any contract, commitment, arrangement
or agreement otherwise than in the ordinary course of business, or passed any
resolution or made any offer (which remains open for acceptance) with respect to
or announced any intention to, or proposed to, effect any of the transactions,
matters or events referred to in this Condition;
and, for the purposes of sub-paragraphs (iii), (iv), (v) and (vi) of this
Condition (j) only, the term 'Amersham Group' shall mean Amersham and its
wholly-owned subsidiaries;
(k) since 31 December 2002, and save as disclosed in the Amersham
Annual Report and Accounts or the Amersham Interim Results or as otherwise
publicly announced by or on behalf of Amersham (by the delivery of an
announcement to a Regulatory Information Service as specified in the Listing
Rules) prior to 10 October 2003 or as otherwise fairly disclosed to GE in
writing by or on behalf of Amersham prior to 10 October 2003:
(i) no material adverse change or deterioration having
occurred in the business, assets, financial or trading position or profits of
the Wider Amersham Group taken as a whole;
(ii) no litigation, arbitration proceedings, prosecution or
other legal proceedings to which any member of the Wider Amersham Group is or
may become a party (whether as a plaintiff, defendant or otherwise) and no
enquiry or investigation by or complaint or reference to any Third Party against
or in respect of any member of the Wider Amersham Group having been instituted
announced or threatened by or against or remaining outstanding in respect of any
member of the Wider Amersham Group which in any such case might be expected to
adversely affect any member of the Wider Amersham Group to an extent which, in
any case, is material in the context of the Wider Amersham Group taken as a
whole;
(iii) no contingent or other liability having arisen or become
apparent to GE which would be likely to adversely affect any member of the Wider
Amersham Group to an extent which, in any case, is material in the context of
the Wider Amersham Group taken as a whole; and
(iv) no steps having been taken which are likely to result in the
withdrawal, cancellation, termination or modification of any licence held by any
member of the Wider Amersham Group which is necessary for the proper carrying on
of its business to an extent which, in any case, is material in the context of
the Wider Amersham Group taken as a whole;
(l) GE not having discovered:
(i) that any financial, business or other information
concerning the Wider Amersham Group publicly disclosed by Amersham or disclosed
to GE at any time by or on behalf of any member of the Wider Amersham Group
prior to 10 October 2003 is misleading, contains a misrepresentation of fact or
omits to state a fact necessary to make that information not misleading to an
extent which, in any case, is material in the context of the Wider Amersham
Group taken as a whole;
(ii) that any member of the Wider Amersham Group is subject to
any liability (contingent or otherwise) save to an extent the same is not
material in the context of the Wider Amersham Group taken as a whole which is
not disclosed in the Amersham Annual Report and Accounts or the Amersham Interim
Results or as otherwise publicly announced by or on behalf of Amersham (by the
delivery of an announcement to a Regulatory Information Service as specified in
the Listing Rules) prior to 10 October 2003 or as otherwise fairly disclosed to
GE in writing by or on behalf of Amersham prior to 10 October 2003; or
(iii) any information which affects the import of any information
disclosed at any time by or on behalf of any member of the Wider Amersham Group;
(m) GE not having discovered that:
(i) any past or present member of the Wider Amersham Group has
failed to comply with any and/or all applicable legislation or regulation, of
any jurisdiction with regard to the use, treatment, handling, storage,
transport, disposal, spillage, release, discharge, leak or emission of any waste
or hazardous substance or any substance likely to impair the environment or harm
human health or animal health or otherwise relating to environmental matters or
the health and safety of any person, or that there has otherwise been any such
use, treatment, handling, storage, transport, disposal, spillage, release,
discharge, leak or emission (whether or not the same constituted a
non-compliance by any person with any such legislation or regulations, and
wherever the same may have taken place) which, in any case, would be likely to
give rise to any liability (actual or contingent) or cost on the part of any
member of the Wider Amersham Group in any case to an extent which is material
and adverse in the context of the Wider Amersham Group taken as a whole;
(ii) there is, or is reasonably likely to be, for that or any
other reason whatsoever, any liability (actual or contingent) of any past or
present member of the Wider Amersham Group which is material in the context of
the Wider Amersham Group taken as a whole to make good, repair, reinstate or
clean up any property or any controlled waters now or previously owned,
occupied, operated or made use of or controlled by any such past or present
member of the Wider Amersham Group, under any environmental legislation,
regulation, notice, circular or order of any government, governmental,
quasi-governmental, state or local government, supranational, statutory or other
regulatory body, agency, court, association or any other person or body in any
jurisdiction; or
(iii) there is, or is reasonably likely to be, any person or class of
persons proposing to bring a claim which is material in the context of the Wider
Amersham Group taken as a whole against any past or present member of the Wider
Amersham Group in respect of, or there is, or is reasonably likely to be, any
liability (actual or contingent) of any past or present member of the Wider
Amersham Group which is material in the context of the Wider Amersham Group
taken as a whole as a result of or relating to, any material, chemical, product
or process now or previously held, used, sold, manufactured, carried out, under
development or research; and
(n) the Implementation Agreement not having been terminated in
accordance with its terms.
For the purposes of these Conditions the 'Wider Amersham Group' means Amersham
and its subsidiary undertakings, associated undertakings and any other
undertaking in which Amersham and/or such undertakings (aggregating their
interests) have a significant interest and the 'Wider GE Group' means General
Electric and its subsidiary undertakings, associated undertakings and any other
undertaking in which General Electric and/or such undertakings (aggregating
their interests) have a significant interest, and for these purposes 'subsidiary
undertaking', 'associated undertaking' and 'undertaking' have the meanings given
by the Companies Act, other than paragraph 20(1)(b) of Schedule 4A of the
Companies Act which shall be excluded for this purpose, and 'significant
interest' means a direct or indirect interest in 20 per cent. or more of the
equity share capital (as defined in the Companies Act) of any undertaking.
2. Subject to paragraph 6, GE reserves the right (but shall be
under no obligation) to waive, in whole or in part, all or any of the above
Conditions, except Conditions (a), (b), (c) and (f). GE shall be under no
obligation to waive or treat as fulfilled any of Conditions (d), (e) or (g) to
(n) inclusive by a date earlier than the date specified or referred to above for
the fulfilment thereof notwithstanding that the other Conditions may at any date
earlier than such date have been fulfilled and that there are at such earlier
date no circumstances indicating that any of such Conditions may not be capable
of fulfilment.
3. In the event that Pre-Condition (a) is waived, the Scheme
will not proceed (or, if applicable, the Offer will lapse) if the European
Commission either initiates proceedings under Article 6(1)(c) of the Merger
Regulation or makes a referral to a competent authority of the United Kingdom
under Article 9(3) of the Merger Regulation and there is a subsequent reference
to the Competition Commission or the Office of Fair Trading refers the
Acquisition or any aspect of such Acquisition to the Competition Commission
before (in each case) the date on which the Scheme becomes effective (or, if
applicable, the later of 3:00 p.m. (London time) on the first closing date of
the Offer and the time and/or date on which the Offer becomes or is declared
unconditional as to acceptances). In such circumstances, neither Amersham nor
any Amersham Shareholder will be bound by any term of the Scheme (or, if
applicable, the Offer will cease to be capable of further acceptance and GE and
the accepting Amersham Shareholders will cease to be bound by acceptances
submitted at or before the time when the Offer so lapses).
4. If GE is required by the Panel to make an offer for the
Amersham Shares (including Amersham Shares represented by Amersham ADSs) under
the provisions of Rule 9 of the City Code, GE may make such alterations to the
terms and conditions of the Acquisition as are necessary to comply with the
provisions of that Rule.
5. GE reserves the right to amend the Conditions at the time
the Acquisition is made to delete references to the Pre-Conditions in Conditions
(d) and (e).
6. GE reserves the right to elect to implement the proposed
acquisition of the Amersham Shares and the Amersham ADSs by way of an Offer. In
such event, the Offer will be implemented on the same terms (subject to
appropriate amendments), so far as applicable, as those which would apply to the
Scheme. In particular, Conditions (a) to (c) inclusive will not apply and the
Offer will be subject to the following further Conditions:
(a) valid acceptances being received (and not, where permitted,
withdrawn) by not later than 3:00 p.m. (London time) on the first closing date
of the Offer (or such later time(s) and/or date(s) as GE may, with the consent
of the Panel or in accordance with the City Code, decide) in respect of not less
than 90 per cent. (or such lower percentage as GE may decide) in nominal value
of the Amersham Shares (including the Amersham Shares represented by Amersham
ADSs) to which the Offer relates, provided that this Condition shall not be
satisfied unless GE and/or any of its wholly-owned subsidiaries shall have
acquired or agreed to acquire, whether pursuant to the Offer or otherwise,
Amersham Shares (including the Amersham Shares represented by Amersham ADSs)
carrying in aggregate more than 50 per cent. of the voting rights then normally
exercisable at general meetings of Amersham; and provided further that this
Condition shall be capable of being satisfied only at a time when all other
Conditions have been satisfied or waived.
For the purposes of this Condition:
(i) shares which have been unconditionally allotted but not
issued before the Offer becomes or is declared unconditional as to acceptances,
whether pursuant to the exercise of any outstanding subscription rights or
otherwise, shall be deemed to carry the voting rights they will carry on being
entered into the register of members of Amersham;
(ii) the expression 'Amersham Shares (including the Amersham
Shares represented by Amersham ADSs) to which the Offer relates' shall be
construed in accordance with sections 428 to 430F of the Companies Act;
(iii) valid acceptances shall be treated as having been received
in respect of any Amersham Shares which GE shall, pursuant to section 429(8) of
the Companies Act, be treated as having acquired or contracted to acquire by
virtue of acceptances of the Offer; and
(iv) as the Offer will be extended into the United States, the
first closing date of the Offer shall be not earlier than the first date
permissible under SEC regulations; and
(b) the Registration Statement, and any post-effective
amendments thereto, having become effective under the Securities Act and no stop
order suspending the effectiveness of such Registration Statement or any part
thereof having been issued and no proceeding for that purpose having been
initiated or threatened by the SEC.
Further Terms of the Acquisition
The Amersham Shares which will be acquired by GE under the Acquisition will be
acquired fully paid or credited as fully paid and free from all liens, charges,
equitable interests, encumbrances, rights of pre-emption and any other rights
and interests of any nature and together with all rights now or hereafter
attaching to them, subject, in the case of dividends, to the entitlements
referred to in Section 4 of the main announcement.
The New GE Shares to be delivered as consideration under the Acquisition will be
fully paid (non assessable) and will rank pari passu in all respects with GE
Shares in issue at the time the New GE Shares are delivered pursuant to the
Acquisition, including the right to receive and retain dividends and other
distributions (if any) paid on or after the Effective Date (or, if applicable,
before the date on which the Offer becomes or is declared unconditional in all
respects). The New GE Shares will be free from all liens, charges, equitable
interests, encumbrances and other third party rights and interests of any nature
whatsoever. Further details of the New GE Shares will be set out in the
Acquisition Document.
APPENDIX III
Implementation Agreement
Under the Implementation Agreement:
(a) Amersham and GE have given each other certain undertakings
regarding implementation of the Scheme (or, if applicable, the Offer);
(b) GE and Amersham have agreed to co-operate with each other
towards satisfaction of the Pre-Conditions and regulatory Conditions;
(c) GE has agreed that it will waive satisfaction of any
immaterial regulatory Condition, provided it is not illegal or unlawful to
proceed with the Acquisition without satisfaction of such Condition;
(d) GE has agreed to make a payment to Amersham of £59.88 million
if the Pre-Conditions and regulatory Conditions are not satisfied or waived by
10 October 2004 provided (i) the non-fulfilment of, or delay in fulfilment of,
the Pre-Conditions or regulatory Conditions is not as a result of any act,
omission or failure to provide information on the part of Amersham in certain
circumstances, (ii) the Amersham Board has not prior to such date withdrawn or
modified (in such a way that the Amersham Board's view is at best neutral) its
recommendation to Amersham Shareholders to vote in favour of the Scheme (or, if
applicable, to accept the Offer), or (iii) no Competing Proposal has been
announced which is subsequently successful;
(e) Amersham has agreed to make a payment to GE of £59.88 million
if (i) a third party acquires Amersham pursuant to a Competing Proposal, or (ii)
the Amersham Board withdraws or modifies (in such a way that the Amersham
Board's view is at best neutral) its recommendation to Amersham Shareholders to
vote in favour of the Scheme (or, if applicable, to accept the Offer), where in
each case the Exchange Ratio is less than the Maximum Exchange Ratio at the time
a Competing Proposal is announced or at the time of the withdrawal of the
recommendation (as the case may be);
(f) Amersham has agreed to certain provisions relating to the
conduct of the Amersham Group's business in the period up to the completion of
the Acquisition, including agreeing to obtain the consent of GE: (i) to the
acquisition or disposal of assets in each case above £125 million; to the
incurring of net indebtedness exceeding £345 million (when aggregated with
existing net indebtedness); and to the payment of dividends exceeding the rate
of growth in earnings per share and in any event exceeding 115 per cent. of the
aggregate amount of dividends paid in respect of the year ended 31 December
2002; (ii) to carrying on business other than in the ordinary course and in all
material respects consistently with past practice; to making certain changes to
its share capital; and to taking action which would require Amersham Shareholder
approval under Rule 21 of the City Code or under the Listing Rules; and
(g) General Electric has agreed to procure performance by GE
Investments of its obligations under the Implementation Agreement.
The Implementation Agreement will terminate, inter alia, if (i) the Regulatory
Pre-Conditions are not satisfied or waived by 10 October 2004 (or such later
date as GE may, with the approval of the Panel and Amersham determine) or (ii)
on the implementation of a Competing Proposal. GE also has certain termination
rights in respect of a breach of the covenants referred to in paragraph (f)
above as follows. Termination rights must be exercised within 30 days (or such
longer period as the Panel may allow) of GE becoming aware of the relevant
breach. Prior to the satisfaction or waiver of the Regulatory Pre-Conditions,
GE can terminate the Implementation Agreement if there is a breach of any of the
covenants referred to in paragraph (f)(i) or a material breach of any of the
covenants referred to in paragraph (f)(ii). After satisfaction or waiver of the
Regulatory Pre-Conditions, the Pre-Condition relating to the termination of the
Implementation Agreement will cease to apply, but GE continues to have the right
to terminate the Implementation Agreement if there is a breach of any of the
covenants referred to in paragraph (f)(i). However, in relation to breaches of
the covenants referred to in paragraph (f)(ii), GE can only terminate the
Implementation Agreement if the breach is of material significance to GE in the
context of the Acquisition and Note 2 on Rule 13 of the City Code will apply.
Any termination of the Implementation Agreement will give GE the right not to
proceed with the Acquisition.
Further details of the Implementation Agreement will be set out in the
Acquisition Document.
APPENDIX IV
Sources and Bases of Information
Save as otherwise set out in this announcement, the following constitute the
bases and sources of certain information and calculations referred to in this
announcement:
Financial Information
(i) The financial information relating to General Electric has
been extracted from its audited annual accounts for the years to which such
information relates and the quarterly unaudited financial statements as
published by General Electric for the relevant periods and unaudited company
data, all of which are prepared in accordance with US GAAP.
(ii) The financial information relating to Amersham has been
extracted from its audited annual accounts for the relevant periods and the
interim unaudited financial statements for the relevant periods as published by
Amersham, all of which are prepared in accordance with UK GAAP.
Price of Amersham Shares
The price of Amersham Shares on any particular date is, unless otherwise stated,
the official closing price on the London Stock Exchange at close of business on
such date, derived from Bloomberg.
Issued Share Capital of Amersham
On 9 October 2003 Amersham had 703,135,827 Amersham Shares in issue.
The directors of Amersham beneficially held 361,537 Amersham Shares on 9 October
2003.
Diluted Share Capital of Amersham
The value placed on the diluted share capital of Amersham by the Acquisition has
been determined on the basis of 703,135,827 Amersham Shares in issue on 9
October 2003 and a net dilution effect of 14,772,684 new Amersham Shares
resulting from the 45,806,719 options for new Amersham Shares outstanding under
the Amersham Share Schemes as at 9 October 2003 and from the 220,000 new
Amersham Shares expected to be issued before the Effective Date (or, if
applicable, the date on which the Offer becomes or is declared unconditional in
all respects).
The net dilution effect of 14,772,684 has been calculated under the treasury
method assuming the exercise of all options for new Amersham Shares under the
Amersham Share Schemes net of the repurchase of Amersham Shares at 800 pence
with the option exercise proceeds.
Price of GE Shares
The price of GE Shares on any particular date is, unless otherwise stated, the
closing quotation on the New York Stock Exchange on such date, derived from
Bloomberg. The GE Share price as at 9 October 2003 is $30.13.
Market Capitalisation of General Electric
The market capitalisation of General Electric as at 9 October 2003 is calculated
on the basis of the above price and 10,040,860,127 GE Shares in issue as at 26
September 2003.
Premium of Acquisition
The terms of the Acquisition value each Amersham Share (on the basis of the
Sterling GE Price at Announcement of £18.32) at 800 pence. The premium that
these terms represent has been calculated by reference to the price of an
Amersham Share of 552 pence on 7 October 2003, the last trading day prior to the
announcement by Amersham that it had received an approach.
Exchange Rates
Except where otherwise indicated, the following exchange rates have been used in
this announcement:
Relating to Date / Period $ / £
9 October 2003 1.66
30 June 2003 1.65
31 December 2002 1.61
1 January 2003 to 9 October 2003 1.61
1 January 2003 to 30 June 2003 1.61
1 January 2002 to 31 December 2002 1.50
Sterling GE Price at Announcement
The Sterling GE Price at Announcement has been calculated on the basis of the
average price (in dollars) of a GE Share calculated on the basis of the daily
volume weighted average price of a GE Share on the New York Stock Exchange for
the ten consecutive trading days prior to, but not including, 9 October 2003,
converted into sterling using the daily 3:00 p.m. (London time) Bank of England
$/£ fix.
Date Daily Volume Weighted Average GE 3:00 PM Bank of Sterling GE Price
Share Price (in $) England Fix ($/£) (in £)
25 Sep-2003 30.6875 1.6594 18.4931
26-Sep-2003 29.9419 1.6617 18.0188
29-Sep-2003 30.3509 1.6517 18.3756
30-Sep-2003 29.8260 1.6712 17.8471
1-Oct-2003 30.3630 1.6613 18.2767
2-Oct-2003 30.6527 1.6694 18.3615
3-Oct-2003 31.0943 1.6669 18.6540
6-Oct-2003 30.9286 1.6710 18.5090
7-Oct-2003 30.6656 1.6717 18.3440
8-Oct-2003 30.3537 1.6608 18.2766
10 Day Average 18.3156
The daily volume weighted average price of a GE Share on the NYSE are sourced
from Bloomberg (using function 'AQR' for the relevant 24 hour period). The
daily 3:00 p.m. (London time) Bank of England fixes for the $/£ exchange rates
are sourced from the Bank of England page on Bloomberg (using function 'BOE').
On the basis of the above table, the Sterling GE Price at Announcement is
£18.32.
Applying the Exchange Ratio on the basis of the Sterling GE Price at
Announcement of £18.32, by dividing £8.00 by £18.32 and then rounding down the
resulting ratio to four decimal places gives an Exchange Ratio at Announcement
of 0.4367 New GE Shares for every Amersham Share.
Maximum Exchange Ratio
The Maximum Exchange Ratio is calculated by taking the Sterling GE Price at
Announcement of £18.32, multiplying it by 78.4 per cent. and by dividing the
resulting price of £14.36 into £8.00 and rounding down the resulting ratio to
four decimal places. This gives a Maximum Exchange Ratio of 0.5571 New GE
Shares for every Amersham Share.
Proforma 2003 Revenue Estimate for GE Healthcare Technologies
The proforma 2003 revenue estimate for the combined GE Healthcare Technologies
business has been calculated by aggregating General Electric's estimate of 2003
revenues for GE Medical and Instrumentarium and consensus analyst estimates for
Amersham.
APPENDIX V
Definitions
The following definitions apply throughout this announcement unless the context
otherwise requires:
'Acquisition' Means the proposed acquisition by GE of Amersham, by means of the
Scheme, or should GE so elect, by means of the Offer;
'Acquisition Document' Means the Scheme Document (together with the relevant forms of
proxy to accompany such document), or should GE elect to make the
Offer, the Offer Document (together with the Forms of Acceptance to
accompany such document);
'Amersham' Means Amersham plc;
'Amersham ADSs' Means American Depository Shares of Amersham, each representing
five Amersham Shares;
'Amersham Annual Report and Means the audited annual consolidated financial statements of the
Accounts' Amersham Group for the financial year ended 31 December 2002;
'Amersham Board' Means the board of directors of Amersham;
'Amersham EGM' or 'Extraordinary Means the extraordinary general meeting of Amersham Shareholders as
General Meeting' may be convened for the purposes of considering and, if thought
fit, approving certain resolutions required to approve and
implement the Scheme;
'Amersham Group' Means Amersham and its subsidiary undertakings;
'Amersham Interim Results' Means the unaudited consolidated financial statements of the
Amersham Group for the six-month period ended 30 June 2003;
'Amersham Securities' Means Amersham Shares and Amersham ADSs;
'Amersham Share Schemes' Means the Amersham Executive Share Option Scheme 1993, the Amersham
2001 Executive Share Option Scheme, the Amersham Share Option
Scheme 1992, the Amersham 2002 Sharesave Plan, the Amersham North
America Stock Option Plan 2000, the Amersham Long Term Incentive
Plan 2002, the Amersham US Employee Stock Purchase Plan and the
Agreement Granting Restricted Share Awards to one of the directors
of Amersham;
'Amersham Shareholders' Means the holders of Amersham Shares;
'Amersham Shares' Means issued and to be issued ordinary shares of 5 pence each in
the capital of Amersham;
'Australia' Means the Commonwealth of Australia and its dependent territories;
'business day' Means a day (excluding Saturdays, Sundays and public holidays) on
which banks generally open for business in London and New York, or
either as specified;
'Canada' Canada, its possessions and territories and all areas subject to
its jurisdiction or any political sub-division thereof;
'City Code' Means The City Code on Takeovers and Mergers of the United Kingdom;
'Combined Group' Means the GE Group, as enlarged by the Acquisition;
'Companies Act' Means the Companies Act 1985;
'Competing Proposal' Means an offer or merger proposed by any third party in respect of
Amersham or for the shares of Amersham;
'Completion Date' or 'Completion' Means the trading day on the NYSE prior to the date on which the
Final Court Order is granted, or should GE elect to make the Offer,
the date on which the Offer becomes or is declared unconditional in
all respects;
'Conditions' Means the conditions to the Acquisition set out in Appendix II;
'Court' Means the High Court of Justice in England and Wales;
'Court Meeting' Means the meeting or meetings of the Amersham Shareholders (or the
relevant class or classes thereof) as may be convened pursuant to
an order of the Court under section 425 of the Companies Act for
the purposes of considering and, if thought fit, approving the
Scheme (with or without amendment);
'Effective Date' Means the date on which the Scheme becomes effective;
'Exchange Ratio' Means on any date the number (expressed as a fraction rounded down
to four decimal places) of New GE Shares to be delivered as
consideration for each Amersham Share under the terms of the
Acquisition determined by dividing 800 pence by the average
Sterling GE Price calculated over the ten consecutive trading day
period up to, but not including, that date;
'Final Court Hearing' Means the date on which the petition to enact the Scheme is heard
by the Court (which is expected to be the business day prior to the
Effective Date);
'Final Court Order' Means the order of the Court sanctioning the Scheme under section
425 of the Companies Act and confirming the reduction of capital
provided for by the Scheme under section 137 of the Companies Act;
'Form of Acceptance' Means the form of acceptance relating to the Offer which will,
should GE elect to make the Offer, accompany the Offer Document;
'GE' Means General Electric and GE Investments, which companies intend
to acquire Amersham jointly under the Acquisition in the
proportions of 79 and 21 per cent., respectively of the issued
share capital of Amersham (or as otherwise agreed by General
Electric and GE Investments);
'GE Group' Means General Electric and its subsidiary undertakings;
'GE Investments' Means GE Investments, Inc., a subsidiary of General Electric;
'GE Medical' Means GE Medical Systems, a division of General Electric;
'General Electric' Means General Electric Company;
'GE Shares' Means $0.06 par value common stock of General Electric;
'Goldman Sachs' Means Goldman Sachs International;
'Implementation Agreement' Means the agreement dated 10 October 2003 between General Electric,
GE Investments and Amersham relating to the Acquisition, details of
which are set out in Appendix III;
'Japan' Means Japan, its cities, prefectures, territories and possessions;
'JPMorgan' Means J.P. Morgan plc;
'Listing Rules' Means the rules and regulations made by the Financial Services
Authority in its capacity as the UK Listing Authority under the
Financial Services and Markets Act 2000;
'London Stock Exchange' Means the London Stock Exchange plc;
'Maximum Exchange Ratio' Means the maximum number of New GE Shares to be delivered as
consideration for each Amersham Share under the terms of the
Acquisition, being 0.5571 New GE Shares for each Amersham Share;
'Meetings' Means the Court Meeting and the Amersham EGM;
'Morgan Stanley' Means Morgan Stanley & Co. Limited;
'New GE Shares' Means the GE Shares to be delivered pursuant to the terms of the
Acquisition, whether new, treasury or previously issued;
'Norway' Means the Kingdom of Norway, its territories and possessions;
'NYSE' Means the New York Stock Exchange;
'Offer' Means, should GE elect to make the Acquisition by way of an offer,
the recommended offer to be made by Goldman Sachs on behalf of GE
once the Pre-Conditions have been satisfied or waived to acquire
all of the Amersham Shares, including as appropriate the offer to
holders of Amersham ADSs in respect of the Amersham Shares
underlying such ADSs, on the terms and subject to the conditions
set out in this announcement and to be set out in the Offer
Document and where the context admits, any subsequent revision,
variation, extension or renewal of such Offer;
'Offer Document' Means, should GE elect to make the Offer, the document to be sent
to Amersham Shareholders and holders of Amersham ADSs which will
contain, inter alia, the terms and conditions of the Offer;
'Official List' Means the Official List of the UK Listing Authority;
'Panel' Means the Panel on Takeovers and Mergers of the United Kingdom;
'Posting Date' or 'Posting' Means the date on which the Acquisition Document is posted to
Amersham Shareholders and holders of Amersham ADSs;
'Pre-Conditions' Means the pre-conditions to the posting of the Acquisition Document
set out in Appendix I;
'Record Date' Means the record date for the Scheme, which is expected to be the
close of business on the business day immediately preceding the
date of the Final Court Order;
'Registration Statement' Means, should GE elect to make the Offer, the registration
statement on Form S-4 relating to the Offer to be filed by General
Electric with the SEC under the Securities Act;
'Regulatory Pre-Conditions' Means Pre-Conditions (a) and (b);
'Scheme' Means, once the Pre-Conditions have been satisfied or waived, the
proposed acquisition of the Amersham Shares by GE by way of a
scheme of arrangement under section 425 of the Companies Act, on
the terms and subject to the conditions set out in this
announcement and to be set out in the Scheme Document;
'Scheme Document' Means the document to be sent to Amersham Shareholders and holders
of Amersham ADSs which will contain, inter alia, the terms and
conditions of the Scheme and will include the notices convening the
Meetings;
'SEC' Means the United States Securities and Exchange Commission;
'Securities Act' Means the US Securities Act of 1933 and the rules thereunder;
'Sterling GE Price' Means on any day the price (in dollars) of a GE Share calculated on
the basis of the daily volume weighted average price of a GE Share
on the NYSE for the ten consecutive trading days prior to, but not
including, that day, converted into sterling using the daily 3:00
p.m. (London time) Bank of England (or any successor organisation)
$/£ fix;
'Sterling GE Price at Announcement' Means £18.32 being the average Sterling GE Price for the ten
consecutive trading days prior to, but not including, 9 October
2003;
'Sterling GE Price at Completion' Means the average Sterling GE Price for the ten consecutive trading
days prior to, but not including, the Completion Date;
'Sterling GE Price at Posting' Means the average Sterling GE Price for the ten consecutive trading
days prior to, but not including, the Posting Date;
'trading day' Means a day on which trading takes place on the NYSE and the London
Stock Exchange, or either as specified;
'UK' or 'United Kingdom' Means the United Kingdom of Great Britain and Northern Ireland;
'UK Listing Authority' Means The Financial Services Authority in its capacity as the
competent authority under the Financial Services and Markets Act
2000; and
'US' or 'United States' Means the United States of America, its territories and
possessions, any State of the United States and the District of
Columbia.
All references to legislation in this announcement are to English legislation unless the contrary is indicated. Any
reference to any provision of any legislation shall include any amendment, modification, re-enactment or extension
thereof.
For the purposes of this announcement, 'subsidiary undertaking' and 'subsidiary' have the meanings under the Companies
Act.
The daily volume weighted average price of a GE Share on the NYSE for calculating the Sterling GE Price will be derived
from Bloomberg (or any replacement service) page 'AQR' (or such other page as may replace such page) using prices
representing all trading information for that relevant 24 hour period ('EDT').
The daily 3:00 p.m. (London time) Bank of England (or any successor organisation) $/£ fix for calculating the Sterling
GE Price will be derived from Bloomberg (or any replacement service) page 'BOE' (or such other page as may replace such
page).
References to '£', 'sterling' and 'pence' are to the lawful currency of the United Kingdom and references to '$' and
'dollars' are to the lawful currency of the United States.
This information is provided by RNS
The company news service from the London Stock Exchange